新型质子泵抑制剂艾普拉唑的研究进展

Research Progress of A New Proton Pump Inhibitor-Ilaprazole

艾普拉唑是新型的质子泵抑制剂。艾普拉唑比同类质子泵抑制剂有更长的半衰期,使其药效维持时间更久,对夜间酸突破防治效果好。在人体内的代谢不受细胞色素同工酶CYP2C19基因多态性的影响。虽然体外实验证实艾普拉唑的代谢主要由CYP3A4/5介导,但是在人体内的实验数据表明CYP3A5酶活性与艾普拉唑的代谢无关。在临床应用中,艾普拉唑无论是单独用药还是联合抗生素用药治疗消化性胃溃疡,其效果都要优于对照药物,在等同的药效下,艾普拉唑的给药剂量要更小。

Ilaprazole is a new proton pump inhibitor（PPI）. Comparing to other PPIs, ilaprazole has longer tl/2 which maintains a longer effective period, and can control well on nocturnal acid breakthrough. The metabolism of ilaprazale in human is not affected by CYP2C19 polymorphisms. It is confirmed that ila- prazole is mainly metabolized by CYP3A4/5 in vitro experiments,but the in vivo data shows that ilaprazole has nothing to do with the CYP3A5 enzyme activity. In clinical practice, ilaprazole is superior to the con- trolled drugs either medication alone or combined with antibiotic drugs for treating peptic ulcer, while with the equivalent efficacy, the dosage of ilaprazole is smaller.